Natural Variation of Equine Infectious Anemia Virus Gag Protein Cytotoxic T Lymphocyte Epitopes  by Zhang, Wei et al.
(
a
a
c
a
l
I
i
c
v
f
t
m
t
c
a
b
n
1
n
c
i
C
A
d
Virology 261, 242–252 (1999)
Article ID viro.1999.9862, available online at http://www.idealibrary.com on
0
C
ANatural Variation of Equine Infectious Anemia Virus Gag Protein
Cytotoxic T Lymphocyte Epitopes
Wei Zhang,1 David B. Auyong, J. Lindsay Oaks, and Travis C. McGuire2
Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, Washington 99164-7040
Received February 11, 1999; returned to author for revision March 17, 1999; accepted June 18, 1999
Two defined cytotoxic T lymphocyte (CTL) epitopes from equine infectious anemia virus (EIAV)-infected horses, equine
leukocyte alloantigen (ELA)-A5.1-restricted epitope 18a, and ELA-A9-restricted epitope 28b-1 were evaluated for conserva-
tion among three wild-type EIAV strains. Epitope 18a variation occurred in all three wild-type EIAV strains, while epitope 28b-1
varied in one strain. Further, 12% amino acid changes occurred in the Gag proteins of a recently isolated wild-type strain,
documenting a much greater Gag protein variation than previously reported. Evaluation of epitope 18a among two virus
isolates from sequential disease episodes in a single horse, H513 (ELA-A5.1/A8), demonstrated that no variation that affected
CTL recognition occurred. H513 PBMC had CTLm to epitope 18a before the occurrence of disease episodes caused by
viruses expressing epitope 18a; however, the frequencies were low (5–15/106 PBMC). Later in infection there was an absence
of disease episodes associated with an increase in CTLm frequency to EIAVWSU5-infected targets, but not epitope 18a-pulsed
targets. Therefore, if CTLm to EIAV epitopes were involved in maintaining the carrier state in H513, they recognized epitopes
other than 18a. © 1999 Academic Press
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1The disease caused by equine infectious anemia virus
EIAV), a lentivirus of horses, is characterized during the
cute phase by recurrent viremia with associated fever,
nemia, and thrombocytopenia. Viremia recurs with de-
reasing frequency for 6 months to a year after infection,
nd then most horses control the virus, becoming life-
ong inapparent carriers (Coggins, 1984; Kono, 1972).
mmune mechanisms are involved in the control of the
nitial viremia because EIAV-infected foals with severe
ombined immunodeficiency do not terminate the initial
iremia, in contrast to termination by infected normal
oals (Perryman et al., 1988). The distinctive features of
his lentiviral infection provide an opportunity to study
echanisms of viral evasion from the immune system in
he acute phase and immune control of the virus in the
arrier phase. Neutralizing antibodies against viral vari-
nts isolated from plasma during disease episodes can
e detected, but delayed appearance of variant-specific
eutralizing antibody in some horses (Carpenter et al.,
987; Kono, 1969) suggests that other immune compo-
ents are also involved in the virus control.
Virus-specific cytotoxic T lymphocytes (CTL) are asso-
iated with the control of the primary viremia in lentiviral
nfections and the maintenance of the nonprogressive
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242tage in simian immunodeficiency virus (SIV)-infected
onkeys (Yasutomi et al., 1993) and in human immuno-
eficiency virus (HIV)-1-infected humans (Bariou et al.,
997; Ogg et al., 1998). EIAV-specific MHC class I-re-
tricted CTL can be detected in the blood early after EIAV
nfection without in vitro stimulation and their appear-
nce is associated with the control of primary viremia
McGuire et al., 1994b). However, despite the generation
f CTL responses during the acute phase of EIAV infec-
ion, viremia still recurs, indicating that the virus escapes
ecognition by CTL. On the other hand, most inapparent
arrier horses have detectable CD81 and CD41 memory
TL (CTLm) recognizing EIAV Gag/Pr or Env or both
roteins (Hammond et al., 1997; McGuire et al., 1997) and
hese CTLm which develop later in infection may recog-
ize common epitopes on virus variants.
Several mechanisms viruses use to escape CTL re-
ponses have been described, including interference of
ntigen presentation pathways by inhibiting viral peptide
ranslocation by transporter associated with antigen pro-
essing (TAP) (Ahn et al., 1997) and by down-regulating
HC class I molecules on the infected cells (Slater and
ampbell, 1997). An important feature of lentiviruses is
he high mutation rate generated by reverse transcrip-
ase (RT) (Bakhanashvili and Hizi, 1993). The resulting
ariant viral proteins can be processed differently, affect-
ng the availability and the affinity of the peptide epitopes
o bind to MHC class I molecules (Couillin et al., 1994;
ssendorp et al., 1996; Borrow et al., 1997; Goulder et al.,
997). Mutations in the epitope can also affect recogni-
ion by the T cell receptor (TCR) on CTL (Purbhoo et al.,
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243VARIANTS OF EIAV-Gag CTL EPITOPES998). Considering these problems, defining highly con-
erved CTL epitopes on lentiviral proteins, if they occur,
ould contribute to strategies for inducing protective CTL
esponses against different viral stains.
We previously mapped CTL epitopes in EIAV Gag
roteins and two nonamer CTL epitopes in the p26 cap-
id protein were defined by CTLm from two EIAVWSU5-
nfected carrier horses (Zhang et al., 1998). Epitope 18a
HPLPNAPLV, aa 209–217 in EIAVWSU5 Gag protein) iden-
ified by CTLm from H513 was equine leukocyte alloan-
igen (ELA)-A5.1 restricted. The ELA-A locus encodes
HC class-I molecules. Epitope 28b-1 (GTTKQKMML, aa
46–354 in EIAVWSU5 Gag protein) identified by CTLm from
532 was ELA-A9 restricted. Both epitopes were en-
oded by the virus (EIAVWSU5) used to infect these horses.
xperiments were done to see if variation occurred in
ag protein sequences from horses infected with three
ild-type EIAV strains and in the two epitopes defined by
TLm from carrier horses. Further experiments were
one to determine if variation of epitope 18a occurred in
wo sequential virus isolates from a single horse or if
TLm were induced to this epitope after the appearance
f these viruses in plasma.
RESULTS
equence variation in Gag p15 and p26 of three
ild-type EIAV strains
To evaluate Gag sequence variation in different wild-type
trains, 13 clones of the EIAVWY gag gene were isolated
rom five independent PCR of spleen DNA, 7 clones of
IAVTX from three independent PCR, and 11 clones of EIAVID
rom four independent PCR were sequenced. Though some
hanges were found in the amino acids translated from
roviral DNA of EIAVWY and EIAVTX compared with EIAVWSU5
Fig. 1), there was 98.4% identity with EIAVWY and 98.1% with
IAVTX. Twenty percent of the changes that occurred in
IAVWY also occurred in EIAVTX (Fig. 1). Random substitu-
ions among nonpolar amino acids A, L, P, F, V, and I were
he most frequent substitutions in EIAVWY and EIAVTX strains
1.6 per clone), indicating that substitution of these amino
cids at these positions did not affect Gag protein function
Fig. 1). Clones from EIAVID were very different, with only
8% amino acid identity with EIAVWSU5 (Fig. 2). Further, five
mino acids present in the other three strains at positions
12 to 116 were deleted from p15 of the EIAVID strain. Finally,
ll clones sequenced from the three wild-type strains had
n E at position 203, while the tissue culture-adapted
IAVWSU5 strain had a D. Sequence variation among clones
ithin each strain demonstrated proviral DNA quasispe-
ies in the spleen tissue from each infected horse.
The large number of amino acid changes encoded by
roviral DNA of the EIAVID strain raised the question of
hether Gag proteins encoded by these sequences
ere functional. Therefore, viral RNA was extracted from
lasma samples of the field EIAVID strain-infected horse cnd a portion (EIAVID strain position 244 to 354) of the
ag gene was amplified by RT–PCR and the cDNA prod-
ct was sequenced. The consensus sequence was iden-
ical to the proviral DNA clone numbers 5, 6, 8, and 9 (Fig.
) from the spleen tissue, except for two amino acid
hanges, one at position 286 (A to G) and another at
osition 321 (M to R) (data not shown). Then, an EIAV-
egative horse (H564) was experimentally inoculated
ith plasma and homogenized spleen tissue from the
aturally EIAVID-infected horse. H564 had a febrile epi-
ode 15 days after inoculation and viral RNA extracted
rom a plasma sample was amplified from two indepen-
ent RT–PCR and cloned. Five clones were sequenced
nd these five clones all had the conserved changes and
he deletion that were present in the proviral DNA clones
rom the field EIAVID-infected horse (Fig. 2). These results
ndicated that the EIAVID sequences in proviral DNA from
pleen tissue were present in plasma viral RNA during
cute disease.
TL epitope variation in wild-type EIAV strains
Amino acid variation in the ELA-A5.1-restricted nonamer
pitope 18a (HPLPNAPLV) occurred in 11 of 13 clones of
IAVWY, all 7 clones of EIAVTX, and all 11 clones of EIAVID
Table 1). Two dominant variants of this epitope were found
n the EIAVWY and EIAVTX strains, a substitution at position 8
L to M), and another at position 4 (P to Q) (Table 1). In the
IAVID strain, a dominant change was at position 1 (H to N)
Table 1). Amino acid variation in the ELA-A9-restricted
pitope 28b-1 (GTTKQKMML) was found only in the EIAVID
train. All the EIAVID clones had the same substitutions in
pitope 28b-1, which was designated 28b-1v. 28b-1v had S,
, R, and L at the 2nd, 3rd, 4th, and 8th positions, respec-
ively (Table 1). Next, it was determined if changes in these
onamer epitopes affected killing by CTLm.
ecognition of epitope variants by CTLm
To analyze the recognition of epitope variants by
TLm, peptides encoded by the wild-type strains were
ade (Table 1). Since CTL were not available from the
ild-type EIAV-infected horses, the effect of variation in
he ELA-A9-restricted peptide epitope 28b-1 was tested
n CTL assays using PBMC effectors from H532 stimu-
ated in vitro with 28b-1. A 100-fold increase in peptide
8b-1v was required for killing and the optimal killing
as 14% below that of targets coated with peptide 28b-1
Fig. 3). These findings indicated that the changes in
eptide 28b-1v encoded by the EIAVID strain gag gene
ffected the amount of peptide required for sensitizing
arget cells for lysis, but did not eliminate lysis by CTLm
ecognizing epitope 28b-1.
Variants of peptide 18a were tested with PBMC effec-
ors from H513 stimulated in vitro with peptide 18a (Fig.
). Peptides 18b and 18e (Table 1) with one amino acid
hange were recognized by CTLm as efficiently as 18a,
e
(
k
p
p
w
1
a
e
v
i
d
c
C
H
m
o
E
a e clone
244 ZHANG ET AL.xcept for peptide 18d, which had a change at position 1
H to N) and lost most of the recognition (Fig. 4). The
illing was also less efficient on target cells pulsed with
eptides with two to three changes; for example, targets
ulsed with peptide 18f with three amino acid changes
ere not killed (Fig. 4). Thus, both epitopes 28b-1 and
8a were variable in wild-type strains and these changes
ffected CTLm lysis of peptide-pulsed target cells. How-
ver, it could was not be determined if these peptide
FIG. 1. Amino acid sequence variation in Gag p15 and p26 of EIAVWY
f EIAVTX (TX) were sequenced (GenBank numbers AF170360–AF1703
IAVWSU5 (WSU5). The dots indicate amino acids identical to those in E
mino acids are indicated on the left by the virus strain followed by thariants could be recognized by CTL from appropriately Ammunized horses. Further experiments were done to
etermine if CTL escape variants of epitope 18a oc-
urred in sequential virus isolates from a single horse.
linical disease in H513 infected with EIAVWSU5
The initial febrile episode started 8 days after infection of
513 and lasted until day 10, while the initial plasma vire-
ia peaked on day 8 and lasted until day 22 (Fig. 5).
VTX strains. Fourteen proviral DNA clones of EIAVWY (WY) and 7 clones
AF170894–AF170900) and the derived amino acids compared with
. To condense the figure clones with identical sequences for each 60
numbers.and EIA
72 and
IAVWSU5nother five febrile episodes began at days 230, 266, 305,
4
w
r
l
p
T
c
a
R
A
c
A
m
n
E
P
e
c
K
s
e
p
t
i
G
a
E
t
A
E
o
245VARIANTS OF EIAV-Gag CTL EPITOPES27, and 492 after infection and each was also associated
ith plasma viremia (designated V1, V2, V3, V4, V5, and V6,
espectively) and thrombocytopenia (Fig. 5). Following the
ast febrile episode at day 492, the horse was in the inap-
arent carrier phase during the last 8 months of this study.
wo viruses, V4 and V5, were isolated and used to infect EK
ells for targets using PBMC effectors isolated and frozen
t different times after infection.
ecognition of V4 and V5 by CTLm from H513
In a previous study, CTLm derived from H513 (ELA-
5.1/A8) at 497 days after infection recognized target
ells either infected with EIAVWSU5 or pulsed with ELA-
5.1-restricted epitope 18a (Zhang et al., 1998). To deter-
ine if H513 CTLm taken 582 days after infection recog-
FIG. 2. Amino acid sequence variation in Gag p15 and p26 of the EIAV
he field EIAVID strain-infected horse and 5 clones of cDNA (IDRT) am
F172098–AF172108 and AF172109–AF172113) and the derived amino aci
IAVWSU5 and the dashes indicate deletions of amino acids. To condense th
n the left by the virus designation followed by the clone numbers.ized V4 and V5, the PBMC were stimulated with tIAVWSU5-infected or peptide 18a-pulsed autologous
BMC. Both stimulated PBMC preparations caused
quivalent lysis of V4-, V5-, and EIAVWSU5-infected target
ells and lysed peptide 18a-pulsed target cells (Fig. 6).
illing of V4- and V5-infected targets with peptide 18a-
timulated CTLm indicated that V4 and V5 were not
scape variants with regard to this epitope since it was
resent on the infecting virus. To confirm this possibility,
he amino acid sequences of V4 and V5 Gag p15 and p26
ncluding the 18a epitope were determined.
ag p15 and p26 sequence conservation in V4
nd V5
To verify that V4 and V5 did not have mutations in the
LA-A5.1-restricted CTL epitope 18a and to determine
. Eleven clones of proviral DNA (ID) amplified from spleen tissue DNA of
from the plasma RNA of H564 were sequenced (GenBank numbers
pared with EIAVWSU5. The dots indicate amino acids identical to those in
e clones with identical sequences for each 60 amino acids are indicatedID strain
plified
ds com
e Figurhe extent of sequence changes, the gag genes encod-
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246 ZHANG ET AL.ng p15 and p26 of 15 clones from five independent PCR
or each virus isolate were sequenced (GenBank num-
ers AF172114–AF172128 and AF172129–AF172143).
ight clones from each virus were identical to the virus
sed for infection, EIAVWSU5. The remaining 14 clones had
few random nonconserved amino acid substitutions
Fig. 7). The average percentage of amino acid change of
hese 14 clones from EIAVWSU5 (359 residues per clone)
as 0.4%. Finally, there were no amino acid changes in
he ELA-A5.1-restricted epitope 18a and its flanking se-
uences in any of the 30 clones, further indicating that V4
nd V5 were not variants that escaped from CTLm rec-
gnizing epitope 18a. Since there was a possibility that
xpansion of V4 and V5 in vitro resulted in selection of
onrepresentative sequences, viral RNA was extracted
rom plasma samples containing V4 and V5, amplified by
T–PCR, and cloned. Five clones each of V4 and V5 were
equenced between Gag amino acids 153 and 254 en-
ompassing epitope 18a. The amino acid sequence of
TABLE 1
Variants of the ELA-A5.1-Restricted CTL Epitope 18a
and the ELA-A9-Restricted Epitope 28b-1
Peptide
esignation Sequence Strain (clone numbers)
18a HPLPNAPLV EIAVWSU5
18b HPLPNAPMV EIAVWY (5, 6, 11), EIAVTX (5–7)
18c HPLQNAPMV EIAVWY (1–3, 7, 10), EIAVTX (1–4)
18d NPLPNAPLV EIAVID (1–6, 8–11), EIAVIDRT (1–5)
18e HPLPNVPLV EIAVWY (4, 8)
18f HPLQNLPMV EIAVWY (12)
28b-1 GTTKQKMML EIAVWSU5
28b-1v GSPRQKMLL EIAVID (1–11), EIAVIDRT (1–5)
FIG. 3. CTLm lysis of EK target cells pulsed with different concen-
rations of ELA-A9-restricted epitope 28b-1 and of the variant peptide
erived from the EIAVID strain (Table 1) for 2 h. PBMC from H532 were
timulated with peptide 28b-1 and used in the CTL assay at a effectorbo target cell ratio of 20:1.wo V4 clones was the same as that for EIAVWSU5, while
he other three V4 and all five V5 clones had the same
equence, except for an M instead of an L in position 8
n the nonomer 18a epitope. This change from one hy-
rophobic amino acid to another was the same as that
escribed for peptide 18b in Table 1. There was no
ifference in killing of peptide 18a- and 18b-pulsed target
ells (Fig. 4), demonstrating that this amino acid change
t position 8 did not result in escape from CTL recogniz-
ng epitope 18a.
TLm frequency following viremic episodes in H513
To evaluate if CTLm recognizing ELA-A5.1-restricted
pitope 18a were present in H513 before the appearance
f V4 and V5, the frequency of CTLm was determined at
ive different time points (Table 2). At day 29 after infec-
ion, there were no detectable CTLm in target cells in-
ected with EIAVWSU5 or pulsed with peptide 18a. At day
90, 16 days before the appearance of V4, low numbers
f CTLm (5 per million PBMC) were detectable to
IAVWSU5-infected and peptide 18a-pulsed target cells.
he frequencies of CTLm increased to 38 per million
BMC recognizing EIAVWSU5-infected target cells and 15
er million PBMC recognizing peptide 18a-pulsed target
ells at day 419, 9 days before the occurrence of V5
Table 1). Then, the frequency of CTLm recognizing EIA-
WSU5 reached 111 per million PBMC at day 635 (Table 2).
he highest frequency of CTL recognizing peptide 18a
as 18 per million PBMC, detected at day 604. These
esults demonstrated that low numbers of CTLm recog-
izing peptide 18a were present in the PBMC of H513
FIG. 4. CTLm lysis of EK target cells pulsed with different concen-
rations of ELA-A5.1-restricted epitope 18a and variant peptides derived
rom the three wild-type strains (Table 1) for 2 h. PBMC from H513 were
timulated with peptide 18a and used in the CTL assay at a effector to
arget cell ratio of 20:1.efore the appearance of V4 and V5 in the plasma.
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247VARIANTS OF EIAV-Gag CTL EPITOPESDISCUSSION
The amino acid variation of p15 and p26 of three
ild-type strains of EIAV ranged from 2 changes in a
IAVWY clone to 46 changes in a EIAVID clone. The pres-
nce of the conserved changes and deletions in the
lasma viral RNA from an EIAVID infected horse indicated
hat the EIAVID Gag proteins were functional. Sequence
ariation in EIAV Gag proteins was thought to be low
ecause the published sequences of five EIAV strains,
ncluding EIAVWSU5, were identical (Kawakami et al., 1987;
cGuire et al., 1994a; Perry et al., 1992; Stephens et al.,
986). This lack of variation may be because one of the
FIG. 5. Body temperature and virus titers in H513 infected with EIAVW
lasma virus titers from the six febrile episodes (designated V1, V2, V
etected only during febrile episodes.
FIG. 6. Recognition of sequential virus isolates V4 and V5 by CTLm f
y EIAVWSU5-stimulated CTLm and autologous EK target cells infected w
ame target cells by peptide 18a-stimulated CTLm. There was no lysishe effector cells used in A and B (not shown). E:T, effector:target.ive strains was EIAVWY and the other four were derived
rom the tissue culture-adapted EIAVWY (Malmquist et al.,
973). The wild-type EIAVWY (Perry et al., 1992) was from
he same original source as the EIAVWY used in this
eport; however, the number of serial horse passages
as different, likely accounting for the sequence differ-
nces. The wild-type strain Gag sequence variation, par-
icularly in the EIAVID strain, together with previous find-
ngs of variation in LTR and the env gene among EIAVID
nd other strains (Leroux et al., 1997; Maury et al., 1997;
ang et al., 1997), further documents the diversity of
ild-type EIAV strains.
rile episodes began 8, 230, 266, 305, 427, and 492 days postinfection.
V5, and V6) were determined on EK cell cultures. Plasma virus was
13 at 582 days postinfection. A shows the percentage of specific lysis
V5, or EIAVWSU5 or pulsed with 20 mM peptide 18a. B shows lysis of the
-infected or peptide 18a-pulsed ELA-A-mismatched EK target cells bySU5. Feb
3, V4,rom H5
ith V4,
of virus
t
e
a
C
E
r
t
c
n
s
1
C
t
a
2
m
c
s
T
n
F
248 ZHANG ET AL.Sequence variation occurred in CTL epitope 18a in all
hree wild-type strains. Variant peptides with two differ-
nt single amino acid changes encoded by EIAVWY
FIG. 7. Comparison of V4 and V5 Gag p15 and p26 sequences with E
equenced, and the amino acids translated and compared with EIAVWSU
o condense the figure clones that had identical sequences for each 60
umbers.
TABLE 2
requency of CTLm per 106 PBMC (95% Confidence Interval)
in H513 Infected with EIAVWSU5
Days postinfection
EK target cells
EIAVWSU5-infected Peptide 18a-pulsed
29 , 2 , 1
290 5 (1–18) 5 (2–12)
419 37 (22–62) 15 (9–27)
608 56 (36–86) 18 (10–45)
637 111 (79–156) 8 (4–18)and/or EIAVTX clones pulsed target cells for killing by
TLm recognizing epitope 18a. Peptide 18c representing
IAVWY and EIAVTX clones with two amino acid changes
equired a 100-fold increase in concentration to pulse
arget cells for killing. However, peptide 18f, with three
hanges which occurred in 1 of 13 clones of EIAVWY, was
ot recognized by CTLm recognizing peptide 18a. Also, a
ingle amino acid change at position 1 (H to N) in epitope
8a that occurred in all 11 clones of EIAVID prevented
TLm killing and confirmed our epitope mapping results
hat this amino acid at position 1 was critical (Zhang et
l., 1998). Changes in the ELA-A9-restricted epitope
8b-1 occurred only in the EIAVID strain and 100-fold
ore of this variant peptide was needed to pulse target
ells for killing. Variation of the two Gag CTL epitopes
5. Fifteen clones of V4 and V5 gag genes encoding p15 and p26 were
ots indicate amino acids that were identical to the sequence EIAVWSU5.
acids are indicated on the left by the virus strain followed by the cloneIAVWSU
5. The d
aminomong wild-type strains of EIAV to sequences that would
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249VARIANTS OF EIAV-Gag CTL EPITOPESot sensitize target cells for killing or for efficient killing
learly demonstrated that these epitopes were not con-
erved among wild-type strains. Since the ELA-A types of
he wild-type strain-infected horses were unknown and
TL were not available, it could not be determined if the
ariants of epitopes 18a and 28b-1 were recognized by
TL in these horses.
To determine whether CTL escape variants occurred
n a horse that made CTL to that epitope, sequential
ariants from an infected horse were studied. CTLm
ecognizing epitope 18a occurred in H513 PBMC at day
97 after infection with EIAVWSU5 which expressed
pitope 18a (Zhang et al., 1998). Amino acid sequence
nalysis of plasma viruses from two sequential disease
pisodes at 305 (V4) and 427 (V5) days after infection
emonstrated that both viruses encoded epitopes rec-
gnized by CTLm to epitope 18a and further, that target
ells infected with these viruses were killed by CTLm
timulated with peptide 18a. The amino acid sequences
ere deduced from proviral DNA sequences from
lasma virus-infected EK cells and from viral RNA ex-
racted from plasma samples.
To determine if CTLm recognizing epitope 18a existed
rior to the appearance of V4 and V5, frequency analysis
as done. Five CTLm per million PBMC recognizing
eptide 18a-pulsed target cells were present prior to the
ppearance of V4 and these increased to 15 per million
BMC prior to the appearance of V5. These frequencies
ere low compared with an average 293 CTLm per
illion PBMC to EIAV-infected targets in five long-term
arrier horses (McGuire et al., 1997) and may not have
een enough to prevent the recurrence of viremia by
iruses encoding epitope 18a. This is supported by the
indings that a single epitope-induced CTL response
ith a CTL precursor frequency of 12 per million PBMC
id not protect against intravenous SIV challenge (Yasu-
omi et al., 1995). The low frequency response to epitope
8a and the failure to control viruses expressing this
pitope are different from the immunodominant CTL re-
ponse to an HIV-1 epitope that resulted in a CTL escape
ariant in a person (Borrow et al., 1997). The data with
TL epitope 18a in H513 are similar to those with ab-
ence of CTL escape variants within five of six epitopes
dentified by CTL from a person with asymptomatic long-
erm HIV-1 infection (Harrer et al., 1996). The difference
etween the frequency of H513 CTLm to EIAVWSU5-in-
ected targets (111 per million PBMC) and to epitope
8a-pulsed targets (8 per million PBMC) during the car-
ier state at 637 days after infection indicated that
pitopes other than 18a were recognized. If CTL were
nvolved in controlling EIAV in H513, then viral antigens
rom recurrent viremias may eventually have stimulated
ufficient CTL in other epitopes to initiate and maintain
he carrier state.
CTLm were undetectable 29 days after infection of513, which is different from our finding that CTL were associated with the control of initial viremia in two other
orses (McGuire et al., 1994b). This variability in CTL
esponses in horses is similar to the finding that 12 and
6% of patients with primary HIV-1 infection did not have
etectable CTL activity (Dalod et al., 1998; Musey et al.,
997). Although control of the initial viremia without de-
ectable CTL responses in H513 suggests the involve-
ent of other mechanisms (Phillips, 1996), the conclu-
ion that CTL were not involved could not be made since
ore sensitive assays using MHC class I–peptide tet-
amer complexes may have detected CTL (Ogg et al.,
998).
In conclusion, CTL epitope 18a was not common
mong three EIAV field strains and a variant of epitope
8b-1 from one field strain required 100-fold more pep-
ide to sensitize target cells for lysis. This does not
reclude other structurally conserved (common)
pitopes recognized by CTL, but the presence of 12%
mino acid changes in one field isolate indicated that
IAV Gag p15 and p26 vary more than previously dem-
nstrated. In contrast to field strains, the only amino acid
hange in epitope 18a that occurred in two viral isolates
rom H513 did not affect CTL killing. In addition, these
iruses were present in plasma even though CTLm rec-
gnizing epitope 18a were present before the appear-
nce of these viruses. The CTLm to epitope 18a were
resent in PBMC in low frequencies, providing a possi-
le explanation for their failure to control these viruses.
owever, an increased frequency of H513 CTLm to other
pitopes on EIAVWSU5-infected target cells during the car-
ier state was consistent with CTL involvement in pre-
enting the occurrence of disease episodes.
MATERIALS AND METHODS
nimals and virus strains
Spleen tissues from horses infected with three wild-
ype EIAV strains were used for DNA extraction in this
tudy. One horse was experimentally infected with the
yoming strain (EIAVWY), which was originally identified
n an EIAV outbreak in Wyoming (Issel and Coggins,
979). The second horse was experimentally infected
ith a strain isolated from a naturally infected horse in
exas (EIAVTX) (McGuire et al., 1971), and a third horse
as from southern Idaho (EIAVID) and had clinical signs
f EIAV and a positive Coggins test (Maury et al., 1997).
fourth horse (H564) was experimentally infected with 1
l of plasma and 5 ml of homogenized spleen tissue
upernatant from the field EIAVID strain-infected horse.
lasma from H564 was collected during the first febrile
pisode and frozen at 280°C for RNA extraction.
Infection of H513 with EIAVWSU5 was as previously de-
cribed (Zhang et al., 1998). EIAVWSU5 is a cell culture-
dapted strain isolated after three sequential passages
f the prototype strain (Malmquist et al., 1973) in horses
nd then biologically cloned by three limiting dilutions on
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250 ZHANG ET AL.quine kidney (EK) cell cultures (O’Rourke et al., 1988).
ody temperature of H513 was recorded daily, and plate-
et count and packed cell volume (PCV) were determined
wice a week during the first year of infection and then
nce a week after that. Plasma samples were collected
nce a week and daily during febrile episodes. Disease
pisodes were defined by body temperature above 39°C,
latelet count below 108,000/ml (McGuire et al., 1997),
nd detectable plasma viremia.
irus isolation, PCR, and RT–PCR amplification
Viruses were isolated from infected horse plasma by
ulturing 106 EK cells with 1 ml plasma for 2 h in a 25-cm2
lask and then washing with DMEM with 5% FBS. These
ells were cultured for 6 days and examined for EIAV
nfection by a fluorescent antibody assay (FA). DNA was
xtracted from infected EK cells using a QIAamp tissue
it (QIAGEN Inc., Germany). Cells (107) were suspended
n 0.2 ml PBS and lysed with 0.2 ml lysis buffer with
roteinase K provided with the kit for 10 min at 70°C.
fter adding 0.21 ml 100% ethanol, the sample was mixed
y vortexing, transferred to a QIAamp spin column, and
entrifuged at 6000 g for 1 min. The column was washed
wo times with wash buffer and dried by centrifuging at
0,000 g for 3 min during the last wash. DNA was eluted
y adding 0.2 ml distilled water preheated at 70°C and
entrifuging at 6000 g for 1 min. Extraction of DNA from
pleen tissue of wild-type strain-infected horses was the
ame as above after lysing 10 mg of tissue with lysis
uffer. Plasma virus RNA was extracted using a RNeasy
iniprep kit (QIAGEN, Germany). One milliliter of plasma
as centrifuged at 58,000 g at 4°C for 1 h and 0.35 ml
ysis buffer was added to the pellet. Following the addi-
ion of 0.35 ml of 70% ethanol to the lysate and mixing by
ipetting, the sample was applied to a RNeasy spin
olumn, the column washed three times, and RNA eluted
ith 40 ml DEPC-treated water.
PCR was performed with a total of 37 cycles: 1 cycle of
min at 94°C; 35 cycles of 1 min at 94°C, 1 min at
3–58°C, and 1 min at 72°C; and 1 cycle of 7 min at
2°C. RT–PCR was performed using reaction conditions
f 50°C for 20 min, 95°C for 10 min, and then 5°C for 5
in. Reactions without adding RT were used as negative
ontrols. Then, PCR was performed by adding the for-
ard primers to the cDNA as described for PCR. The
rimer pairs used for amplifying DNA from infected EK
ells or spleen DNA of EIAVWY and EIAVTX strains were (i)
IAVWSU5 LTR 232 (TTACAGTAGACAAGTGCTTG) and
IAVWSU5 gag 1436 (GCGCCTCGAGTTATATCGG-
AAAGTTTGTTTCTG) for primary PCR and (ii) EIAVWSU5
ag 126 (GCGCGAATTCAAGATGGGAGACCCTTTGACA)
nd EIAVWSU5 gag 1202 (GCGCCTCGAGTTAAAGTGCTTT-
GCCAATAACAT) for nested PCR. The primer pairs used
n PCR reactions for EIAVID strain were (i) EIAVWSU5 LTR
32 and EIAVWSU5 gag 1436 for primary PCR and (ii) mIAVWSU5 gag 81 (TCTTCTGGAGGTGTTCCTGG) and EIA-
WSU5 gag 1302 (TAAATGTCCTGGCTTCCCAC) for nested
CR. The primer pairs used in RT–PCR for EIAVID strain
ere (i) EIAVWSU5 gag 81 and EIAVWSU5 gag 1302 for RT–
CR and (ii) EIAVID gag 126 (ATGGGAGACTCACTGA-
ATG) and EIAVID gag 1179 (CACTCTGAAGT-
CTCTAGCC) for nested PCR. The amplified products
rom PCR and RT–PCR were cloned into TA cloning
ectors, pCRII (Invitrogen), and the clones were se-
uenced.
n vitro stimulation of CTLm
PBMC were separated from the blood of EIAV-infected
orses H513 and H532 (Zhang et al., 1998) by layering
eukocyte-rich plasma over Histopaque and centrifuging
McGuire et al., 1994b). To generate CTLm, 106 PBMC
ere cultured with 106 irradiated, EIAV-infected or pep-
ide-pulsed autologous PBMC in each well of a 24-well
late with 1 ml DMEM containing 10% FBS and 20 mM
EPES. The stimulator PBMC were prepared by irradi-
ting 108 autologous PBMC with 3 krad of gamma irra-
iation, mixing with 5 ml of 106 TCID50/ml EIAVWSU5 or
arious peptides at 20 mg/ml, and incubated at 37°C for
h. After stimulation for 7 days, 5 3 105 viable cells were
estimulated with 106 stimulator cells in 1 ml medium/
ell containing 10 U/ml recombinant human IL-2 (rIL-2)
Gibco BRL, Grand Island, NY). After 4 days, the restim-
lated PBMC were split 1:2 with fresh medium and rIL-2,
xpanded for another 3–4 days, and used as effector
ells in CTL assays.
ytotoxicity assay
Cytotoxic assays using EK target cells expanded from
idney biopsies (McGuire et al., 1994b) and infected with
IAVWSU5 or sensitized with synthetic peptides were as
reviously described (McGuire et al., 1994b; Zhang et al.,
998). The formula % specific lysis 5 [(E-S)/(M-S)] 3 100,
here E is the mean of six test wells, S is the mean
pontaneous release from six wells without effector
ells, and M is the mean maximal release from six wells
ith 3% Triton X-100, was used. The standard error (SE)
f the percentage of specific lysis was calculated. Only
ssays with a spontaneous lysis of , 30% were used.
imiting dilution assay and data analysis
The CTLm frequency in EIAV-infected horses was de-
ermined using the limiting dilution assay (McGuire et al.,
997). Briefly, PBMC were diluted to 1250, 2500, 5000,
0,000, and 20,000 cells/well in 0.1 ml DMEM containing
5% fetal bovine serum and 15% calf serum (DMEM1) in
6-well (round-bottom) plates. Four sets of 24 wells for
ach PBMC dilution were stimulated for 12 days before
ssaying for CTL activity on 4 different target cells, in-
luding EIAVWSU5-infected autologous and ELA-A-mis-
atched EK cells and peptide pulsed or nonpulsed nor-
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251VARIANTS OF EIAV-Gag CTL EPITOPESal autologous EK cells. Diluted PBMC were stimulated
ith monocytes infected with EIAVWSU5 and incubated for
days in a humidified chamber at 37°C with 5% CO2.
hen, 0.1 ml of DMEM1 containing 40 U/ml of recombi-
ant human IL-2 (Gibco BRL) was added to each well
nd the cells were incubated for another 6 days before
eing resuspended and transferred to a well of EK target
ells labeled with 51Cr. The plates were incubated at
7°C for 17 h and 0.1 ml of supernatant was removed to
etermine 51Cr release. Each of the 24 wells of the
imiting dilution assay was scored positive or negative
ased on whether the 51Cr release exceeded a specific
ysis threshold (Carmicheal et al., 1993). The threshold
as calculated as the mean spontaneous release 1 10%
f the specific release. The limiting dilution data were
nalyzed by calculating the frequency of CTL and a 95%
onfidence limit using the maximum likelihood method
nd testing the goodness of fit of the data with the
oisson model by calculating x2 (Fazekas De St. Groth,
982).
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